Sanofi’s hyaluronic acid product lines, Synvisc and Synvisc-One, posted revenue of USD $76.4.1MM in 1Q19, flat vs. 1Q18.
U.S. revenue loss diminished from 2018, -2.2% vs. 1Q18 Emerging markets were strong, with +15.4% revenue vs. last year
Synvisc and Synvisc-One sales on an as-reported basis are as follows ($MM).
1Q19 1Q18 % Chg % Chg Orthobiologics $76.4 $76.4 $0.0 0.0%
Synvisc and Synvisc-One sales by geographic region are as follows ($MM).
Geographic Region 1Q19 1Q18 % Chg % Chg US $49.4 $50.6 -$1.1 -2.2% Ex-US $27.0 $25.8 $1.1 4.3% Europe $6.7 $6.7 $0.0 0.0% Emerging Markets $16.9 $14.6 $2.2 15.4% Rest of World $3.4 $4.5 -$1.1 -25.0% Total $76.4 $76.4 $0.0 0.0%
Sources: Sanofi
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email .
Favorite
Sanofi’s hyaluronic acid product lines, Synvisc and Synvisc-One, posted revenue of USD $76.4.1MM in 1Q19, flat vs. 1Q18.
U.S. revenue loss diminished from 2018, -2.2% vs. 1Q18
Synvisc and Synvisc-One sales on an as-reported basis are as follows...
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
